Fas antigen expression and outcome of oral squamous cell carcinoma.
Paraffin sections of biopsy specimens obtained from 46 patients with oral squamous cell carcinomas were stained with both anti-peptide antibody against human Fas antigen and monoclonal mouse antibody against human proliferating cell nuclear antigen (PCNA). The patients received chemotherapy with a combination of carboplatin and peplomycin sulfate or mitomycin C and peplomycin sulfate before surgery. The relation between the expression of Fas antigen and the clinical features of each case was examined. The correlation between PCNA and Fas antigen expression was also studied. The mean PCNA labeling index of the 22 Fas-negative cases was 46.9%, which was significantly higher than that of the 24 Fas-positive cases (39.5%). Strong correlations were found between the expression of Fas antigen and the response to chemotherapy, tumor recurrence, and survival. The Fas-negative group had only a minor response to chemotherapy and a poor outcome, whereas the Fas-positive group had a better response to chemotherapy and a good outcome. Although lymph node metastasis was significantly related to survival, there was no correlation between Fas antigen expression and lymph node metastasis. The Kaplan-Meier survival curve of patients positive for Fas antigen was significantly better than that of patients negative for Fas antigen. Our results suggest that Fas antigen expression is an independent predictor of outcome whose usefulness should be evaluated in prospective studies.
Muraki
Y
Y
First Department of Oral and Maxillofacial Surgery, Kyushu Dental College, Kitakyushu, Japan.
Tateishi
A
A
Seta
C
C
Fukuda
J
J
Haneji
T
T
Oya
R
R
Ikemura
K
K
Kobayashi
N
N
D000206:Actuarial Analysis; D000328:Adult; D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D016190:Carboplatin / Q000008:administration & dosage; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000276:immunology*; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage; D009062:Mouth Neoplasms / Q000188:drug therapy / Q000276:immunology*; D017663:Peplomycin / Q000008:administration & dosage; D018809:Proliferating Cell Nuclear Antigen / Q000187:drug effects / Q000378:metabolism; D016896:Treatment Outcome; D019014:fas Receptor / Q000187:drug effects / Q000378:metabolism*
D000903:Antibiotics, Antineoplastic; D018809:Proliferating Cell Nuclear Antigen; D019014:fas Receptor; D016685:Mitomycin; D017663:Peplomycin; D016190:Carboplatin